Replimune
Edit

Replimune

http://www.replimune.com/
Last activity: 25.08.2026
Active
Categories: BodyClothingDeliveryDrugFutureHealthTechMedTechPlatformProductPublic
Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse.
Mentions
27
Location: United States, Massachusetts, Woburn
Total raised: $85M
Twitter
LinkedIn
Email

Investors 5

Funding Rounds 2

DateSeriesAmountInvestors
08.09.2017Series B$55MForesite C...
24.09.2015Series A$30M-

Mentions in press and media 27

DateTitleDescription
25.08.2026HHS plans new FDA deputy commissioner roles for technology and drugs, sources sayThe Department of Health and Human Services is planning to appoint deputy commissioners for technology and drugs at the FDA, creating new roles at the agency, CNBC has learned. Like existing deputy commissioner roles, the two new positions ...
15.08.2026Replimune Raises $150 Million To Fund TUDRIQEV Launch And Confirmatory TrialReplimune completed a $150 million financing as the biotechnology company prepares to commercially launch TUDRIQEV following FDA accelerated approval and continues the Phase 3 confirmatory trial required to support the treatment’s longer-te...
31.07.2026Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more-
30.07.2026Daily Stock Market Live S&P 500 closes higher Friday as Amazon surges; Dow posts fourth straight winning month: Live updatesThe major averages were markedly higher Friday, the last trading session in July, as investors looked past rising bond yields and Amazon shares jumped. The Nasdaq Composite rose 1% to end at 25,373.85, while the S&P 500 added 0.7% to cl...
17.06.2026UniQure to seek FDA approval for Huntington’s disease gene therapy after previous clash with agencyUniQure said it plans to seek approval for its experimental gene therapy for Huntington’s disease. The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its ...
29.05.2026Replimune to resubmit twice-rejected drug for approval after FDA shakeupReplimune said it plans to resubmit its melanoma drug for approval following two earlier rejections. The move follows the departure of Food and Drug Administration Commissioner Marty Makary. Replimune was among the drugmakers that had criti...
12.05.2026Marty Makary resigns as FDA commissioner following industry and White House backlashFDA Commissioner Marty Makary is out the job, and a deputy at the agency will take over temporarily, President Donald Trump said. Makary’s tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from d...
01.08.2025The Melanoma Research Foundation Launches its Annual Philadelphia 5K Fundraiser with a Goal of $110,000 in Support of its MissionThe Melanoma Research Foundation (MRF) is thrilled to announce one of the next events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we wi...
26.06.2025Miss Illinois Teen USA Emcees Chicago Miles for Melanoma 5K to Raise Critical Funds for Melanoma ResearchThe Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be ho...
02.10.2024ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York CityConference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In